Market Trends of Psoriatic Arthritis Therapeutics Industry
Immunosuppressants Segment is Expected to Hold a Large Share in the Market
- Immunosuppressants are expected to experience the fastest growth in the psoriasis drugs market during the forecast period. This is due to several factors, including their improved safety and efficacy compared to other drug classes, which has consistently led to increased patient adoption. Major approved antibodies targeting interleukins, such as Taltz (ixekizumab), Cosentyx (secukinumab), Siliq (brodalumab), Tremfya (guselkumab), Ilumya (tildrakizumab), SKYRIZI (risankizumab), and others, are aiding in the adoption of immunosuppressants among the patient population.
- In addition, the approvals of drugs by regulatory authorities, such as the recent approval of Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, by the United States Food and Drug Administration (USFDA) in September 2022 for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and the approval of the first and only biologic medication, ustekinumab (STELARA), for the treatment of pediatric patients aged 6 years or older with active psoriatic arthritis (PsA) in August 2022, are also contributing to the growth of the segment.
- Moreover, according to data from PubMed published in December 2022, immunosuppressants used for the treatment of psoriatic arthritis are tolerable and safe, further increasing the demand for these drugs in the market.
- Therefore, with the significance of immunosuppressants and new launches contributing to the market segment's growth, it is expected to show significant growth over the forecast period.
Understand The Key Trends Shaping This Market
Download Sample
North America is Expected to Dominate the Market During the Forecast Period
- North America is projected to be the dominant player in the psoriatic arthritis therapeutics market due to several factors. One of the primary reasons for this is the region's growing prevalence of psoriatic arthritis and obesity, which has increased awareness of the condition. The Centers for Disease Control and Prevention (CDC) reported in September 2021 that adult obesity rates in the United States are increasing, with twelve states reporting a prevalence of 35% or higher.
- Developed countries such as the United States and Canada have established healthcare systems that have a rapid adoption rate for new drugs, therapies, and technologies. As a result, expenditures on psoriatic arthritis therapeutics are expected to rise as the disease becomes more prevalent in the future. Furthermore, a study published in April 2022 by the National Library of Medicine indicated that individuals with severe psoriasis are more likely to develop psoriatic arthritis, which increases the severity of the disease.
- Given these factors, the North American market's growth in psoriatic arthritis therapeutics is expected to accelerate over the forecast period.
Get Analysis on Important Geographic Markets
Download Sample
